Trial · NCT07114861
The KN510713 Study in Combination With mFOLFIRINOX
NCT07114861, Phase 1, Phase 2, Recruiting, New Cancer Cure-Bio Co.,Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The KN510713 Study in Combination With mFOLFIRINOX. Trials, record NCT07114861. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07114861
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The KN510713 Study in Combination With mFOLFIRINOX
- NCT number
- NCT07114861
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- New Cancer Cure-Bio Co.,Ltd.
- Conditions
- Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX, Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX
- First posted
- 2025-08-11
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of occurrences, affected subjects with adverse events. | Through study completion, an average of 12 months | Safety Evaluation(Adverse Event, Laboratory Test, Vital Signs, Electrocardiogram) |
| Primary | The frequency and percentage of Dose-Limiting Toxicitys | 4 weeks | Safety/Tolerability Evaluation(Dose-Limiting Toxicity, Part 1 Subjects only) |
| Secondary | Objective Response Rate | Through study completion, an average of 12 months | The proportion of subjects whose best overall response (BOR) is assessed as complete response (CR) or partial response (PR). ORR = CR + PR |
| Secondary | Disease Control Rate | Through study completion, an average of 12 months | The proportion of subjects whose BOR is assessed as CR, PR, or stable disease (SD). DCR = CR + PR + SD |
| Secondary | Duration of Response | Through study completion, an average of 12 months | The duration from the date of the first assessment of CR or PR to the date of the first assessment disease progression (PD) |
| Secondary | Progression-Free Survival | Through study completion, an average of 12 months | The time from the start date of IP administration to the earlier of either PD based on RECIST ver1.1 or death from any cause |
| Secondary | Overall Survival | Through study completion, an average of 12 months | The time from the start date of IP administration to the date of death from any cause |
| Other | Changes in Phospholipids | Screening, 8 weeks | The number of subjects, mean, standard deviation, median, minimum, and maximum will be presented for changes at each time point. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07114861
GET https://conductscience.org/api/trials/v1/NCT07114861/registered